Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,470.00
(
-1.06%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
0.00%
)
Bitcoin
70,718.00
(
0.29%
)
News Focus
News Focus
Post# of 257264
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

mcbio

Send PM Follow Ignore
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

mcbio

Re: jq1234 post# 148098

Monday, 09/03/2012 9:00:40 PM

Monday, September 03, 2012 9:00:40 PM

Post# of 257264

I agree with Peter Cabo is a lot better bet on Xtandi/Zytiga failure because data showed there wasn't much difference in Xtandi/Zytiga treated vs chemo treated - this is an important factor to me in EXEL valuation.

Has cabo ever led to a CR in prostate cancer, as OGX-427 did in its most recent Phase 2 trial?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today